Skip to content
Company Analysis

TransMedics Group, Inc. TMDX

A comprehensive view of key metrics, scores, and financial health for TransMedics Group, Inc.

Overview of TransMedics Group, Inc.

TMDX NGM
Healthcare Medical Devices Framework: Medical Devices & Diagnostics Mid Cap
TransMedics Group, Inc. (TMDX), is a Mid Cap company, in the Medical Devices industry, last closed at $66.67, about 54.8% overvalued vs fair value, -46.7% 1Y return, placing in the top 25% of its sector.
Metrics P/E 25.9× Rev Growth 37.1% ROE 54.2% Gross Margin 59.9%
USD 66.67
1.03%
(Delayed)
• Vol 90d: 49.5%
52-Week Range
Market Cap
$2.31B
Enterprise Value
$2.35B
Overall Score
View breakdown
Overall
Growth
Good
Profitability
Good
Health
Good
Efficiency
Fair
Valuation
Good
Growth
Good
Profitability
Good
Health
Good
Efficiency
Fair
Valuation
Good
Completeness: 88%
Confidence: 94%
Updated: Oct 31
Top Beats

Quick Facts

Website https://www.transmedics.com
HQ Andover, MA
Employees 898
Fiscal year Dec 31

Next Events

Earnings Nov 5 Call: Nov 5

Fair Value Snapshot

Bear Base Bull
$27
$30
$34
Current: $66.67 -55% vs base

Engine Room Money Flow™

Mid Cap

Medical Devices & Diagnostics - Where revenue goes and how value is created

Flow Steps
Total Revenue
$605.5M
37.1%%
Gross Profit
$362.8M
38.4%%
Operating Income (GAAP)
$108.6M
189.6%%
EBITDA
$148.5M
112.3%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Medical Devices & Diagnostics

Quality & Reliability Indicators

Gross Margin
59.9%
Good

Gross Profit / Revenue — primary moat signal for MedTech. ≥65% indicates IP-protected consumables with strong pricing power.

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health some concerns
Moderate efficiency issues detected. Review active leaks below for improvement areas.
2
Active Leaks
2/2
Improving
0
High Impact
0
Critical
Locked Leak
Upgrade to view details
Premium
Moat Analysis Medical Devices & Diagnostics

Competitive Advantage Assessment

Evaluating TransMedics Group, Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
70
/100
Moderate
Scores based on quantitative metrics and qualitative factors
Full moat analysis

Key strengths

  • Strong FCF Generation FCF margin quality is top-tier vs peers (score 0.97). High FCF conversion confirms strong earnings quality.
  • Superior Capital Returns Capital return quality is top-tier (score 0.86). High ROIC indicates the business is reinvesting at attractive rates.

Key risks

  • Gross Margin Volatility Gross margin stability is poor (score 0.38). Margin volatility undermines the consumable moat thesis.
  • Revenue Growth Slowing Revenue growth trend is weak (score 0.38). Slowing top-line momentum reduces the future consumable base.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Developing
47
Premium

Signals, strengths and risks for Pricing Power & Consumable Moat

Premium

Signals, strengths and risks for R&D Pipeline & Capital Returns

Premium

Signals, strengths and risks for FCF Quality & Cash Conversion

Premium

Signals, strengths and risks for Commercial Execution

Premium

Signals, strengths and risks for Capital Structure & Resilience

Premium

Signals, strengths and risks for Growth Durability

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Healthcare: MedTech (Devices & Supplies) vs Industry Peers 95% Coverage
Trade-Off Triangle Visualization A ternary plot showing TMDX's balance between Growth (39.1%), Profitability (35.9%), and Safety (25.1%). Growth 39% Safety 25% Profitability 36%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

90th percentile vs peers
91
Key Signals
Rev Growth YoY 37.1% 89p EPS Growth YoY 3.66 97p Revenue CAGR 3Y 86.4% 94p TSR 30.4% 75p Asset Growth YoY 32.9% 88p
Strengths
  • Growth performance in top 20% of peers (percentile: 90)
  • Rev Growth YoY in top 20% of peers (37.1%, 89th percentile)
  • EPS Growth YoY in top 20% of peers (3.66, 97th percentile)
  • Revenue CAGR 3Y in top 20% of peers (86.4%, 94th percentile)
Risks

No significant risks identified for this axis.

Profitability

83th percentile vs peers
83
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

58th percentile vs peers
58
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for TransMedics Group, Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$30.16
- - -
-54.8% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000